# Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

> **NCT06548139** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 120 (estimated)

## Conditions studied

- Rabies Virus Infection

## Interventions

- **DRUG:** Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg
- **DRUG:** Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg
- **DRUG:** Rabies Human Immunoglobulin (HRIG)
- **BIOLOGICAL:** Lyophilized rabies vaccine for human use (Vero cells)

## Key facts

- **NCT ID:** NCT06548139
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-08-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548139, "Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06548139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*